Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination With Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects With Mantle Cell Lymphoma

NCT02717624 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02717624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02717624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination With Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects With Mantle Cell Lymphoma
Lead sponsor
Acerta Pharma BV
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 20, 2016
Completion date
August 20, 2027
Enrollment
72 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma (mcl)